Can a diabetes drug boost dialysis efficiency for kidney patients?

NCT ID NCT05671991

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 01, 2026 · Last updated Jun 16, 2026 · Updated 4 times

Summary

This study tests if empagliflozin, a diabetes drug, can reduce sugar absorption during peritoneal dialysis in 30 adults with end-stage kidney disease. Participants will receive either the drug or a placebo in a crossover design, followed by an 8-week open-label phase where everyone gets the drug. The goal is to see if it helps dialysis work better by lowering glucose uptake.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE ON DIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Yale University
RECRUITING

New Haven, Connecticut, 06510, United States

Contact

Conditions

Explore the condition pages connected to this study.

END STAGE RENAL DISEASE ON DIALYSIS

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

END-STAGE RENAL DISEASE ON PERITONEAL DIALYSIS